Technical breakout strategies depend on two separate elements: a stock that has already proven its trend strength and a chart pattern that offers a controlled entry point. ARCUS BIOSCIENCES INC (NYSE:RCUS) is a clinical-stage biopharmaceutical company that currently scores at the top of both measures, making it a candidate for investors who trade momentum with defined risk.
Strong technical foundation
The ChartMill Technical Rating is designed to measure the overall technical health of a stock by combining long and short term trends, moving average positioning, and relative strength. A score of 10 out of 10 means RCUS is showing the kind of sustained uptrend that technical investors typically want to see before considering a long position.
Several concrete factors support that top rating:
- The short term and long term trends are both positive.
- The stock has outperformed 97% of all stocks over the trailing year.
- Within the Biotechnology industry, it outperforms 88% of 512 comparable stocks.
- The price is trading near its 52 week high of 31.735, with the S&P 500 also near its own highs.
- The 20, 50, 100, and 200 day moving averages are all rising, with price above each of them.
That combination of trend direction, breadth of participation, and relative strength is what separates a genuinely strong stock from one that is merely bouncing. For a more detailed look at the indicators behind this score, investors can review the technical analysis report.
A consolidation pattern worth watching
A high technical rating alone does not tell you when to buy. A stock can be in a strong uptrend but still be extended after a sharp move, leaving little room for a well-placed stop. That is why the Setup Quality score matters. It measures whether a stock is forming the kind of consolidation base that can produce a cleaner breakout entry.
RCUS receives a Setup Rating of 9 out of 10. The stock has been trading in a relatively tight range between roughly 26.91 and 31.58 over the past month and is currently near the upper end of that range. The technical report identifies only two important resistance areas, one at 31.00 on the weekly timeframe and one at 31.57 on the daily timeframe. With price at 30.76, there is limited overhead supply before a potential breakout.
The report also points to a support zone from 28.75 to 29.20, which is reinforced by multiple trend lines and moving averages on the daily chart. That provides a logical reference point for risk management. Based on the nearest support and resistance levels, the suggested breakout setup would be:
- Entry: a buy stop above resistance at 31.01
- Exit: a stop loss below support at 28.74
- Worst case loss: 2.27 points, or about 7.32%
- Position size: 13.66% of capital for a 1.00% portfolio risk
The Setup Quality score also benefits from signs that large players have been accumulating the stock recently, as measured by the Effective Volume indicator. In addition, the stock trades with an average daily volume of roughly 1.32 million shares, which helps ensure that entries and exits can be executed without excessive slippage.
Key observations at a glance
- Technical Rating: 10 out of 10
- Setup Rating: 9 out of 10
- Relative strength: 97.93
- Average true range: 4.26% of price
- 52 week range: 10.55 to 31.735
- Recent price: 30.76
Why both scores matter for breakout trading
The technical rating tells you whether the stock deserves your attention; the setup rating tells you whether the current chart offers a favorable risk/reward moment. Combining both filters is the core idea behind the Technical Breakout Setups approach. A stock with a rating of 10 and a setup of 9 is not just rising, it is pausing in a controlled way after a strong advance. That pause gives traders a defined area to place a buy stop and a support zone below which to set a protective stop.
There are still risks. Clinical-stage biopharmaceutical companies can be highly sensitive to pipeline news, and the stock's 190% gain over the past year means sentiment is already positive. The automated trade suggestion is based strictly on chart levels and should be checked against upcoming earnings or clinical catalysts. A wider stop may also be appropriate for investors looking at a longer holding period.
Finding more stocks with this profile
The same combination of high technical strength and high setup quality can be applied across the market. Investors who want to screen for other names with similar breakout characteristics can use the Technical Breakout Setups screen to generate a fresh list of candidates.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Arcus Biosciences (NYSE:RCUS) Flashes a High-Quality Technical Breakout Setup
Technical breakout strategies depend on two separate elements: a stock that has already proven its trend strength and a chart pattern that offers a controlled entry point. ARCUS BIOSCIENCES INC (NYSE:RCUS) is a clinical-stage biopharmaceutical company that currently scores at the top of both measures, making it a candidate for investors who trade momentum with defined risk.
Strong technical foundation
The ChartMill Technical Rating is designed to measure the overall technical health of a stock by combining long and short term trends, moving average positioning, and relative strength. A score of 10 out of 10 means RCUS is showing the kind of sustained uptrend that technical investors typically want to see before considering a long position.
Several concrete factors support that top rating:
That combination of trend direction, breadth of participation, and relative strength is what separates a genuinely strong stock from one that is merely bouncing. For a more detailed look at the indicators behind this score, investors can review the technical analysis report.
A consolidation pattern worth watching
A high technical rating alone does not tell you when to buy. A stock can be in a strong uptrend but still be extended after a sharp move, leaving little room for a well-placed stop. That is why the Setup Quality score matters. It measures whether a stock is forming the kind of consolidation base that can produce a cleaner breakout entry.
RCUS receives a Setup Rating of 9 out of 10. The stock has been trading in a relatively tight range between roughly 26.91 and 31.58 over the past month and is currently near the upper end of that range. The technical report identifies only two important resistance areas, one at 31.00 on the weekly timeframe and one at 31.57 on the daily timeframe. With price at 30.76, there is limited overhead supply before a potential breakout.
The report also points to a support zone from 28.75 to 29.20, which is reinforced by multiple trend lines and moving averages on the daily chart. That provides a logical reference point for risk management. Based on the nearest support and resistance levels, the suggested breakout setup would be:
The Setup Quality score also benefits from signs that large players have been accumulating the stock recently, as measured by the Effective Volume indicator. In addition, the stock trades with an average daily volume of roughly 1.32 million shares, which helps ensure that entries and exits can be executed without excessive slippage.
Key observations at a glance
Why both scores matter for breakout trading
The technical rating tells you whether the stock deserves your attention; the setup rating tells you whether the current chart offers a favorable risk/reward moment. Combining both filters is the core idea behind the Technical Breakout Setups approach. A stock with a rating of 10 and a setup of 9 is not just rising, it is pausing in a controlled way after a strong advance. That pause gives traders a defined area to place a buy stop and a support zone below which to set a protective stop.
There are still risks. Clinical-stage biopharmaceutical companies can be highly sensitive to pipeline news, and the stock's 190% gain over the past year means sentiment is already positive. The automated trade suggestion is based strictly on chart levels and should be checked against upcoming earnings or clinical catalysts. A wider stop may also be appropriate for investors looking at a longer holding period.
Finding more stocks with this profile
The same combination of high technical strength and high setup quality can be applied across the market. Investors who want to screen for other names with similar breakout characteristics can use the Technical Breakout Setups screen to generate a fresh list of candidates.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »